Recruiting Rheumatoid Arthritis Studies in Lakeland
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects...
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to...
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-...
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage...
About Rheumatoid Arthritis Clinical Trials in Lakeland
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.
There are currently 4 rheumatoid arthritis clinical trials recruiting participants in Lakeland, FLORIDA. These studies are seeking a combined 1,256 participants. Research is being sponsored by Belite Bio, Inc, AbbVie, Takeda and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Rheumatoid Arthritis Clinical Trials in Lakeland — FAQ
Are there rheumatoid arthritis clinical trials in Lakeland?
Yes, there are 4 rheumatoid arthritis clinical trials currently recruiting in Lakeland, FLORIDA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Lakeland?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lakeland research site will contact you about next steps.
Are clinical trials in Lakeland free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lakeland studies also compensate for your time and travel.
What rheumatoid arthritis treatments are being tested?
The 4 active trials in Lakeland are testing new therapies including novel drugs, biologics, and treatment approaches for rheumatoid arthritis.
Data updated March 2, 2026 from ClinicalTrials.gov